Status:

TERMINATED

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Lead Sponsor:

Genentech, Inc.

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA. The study will enroll approxima...

Eligibility Criteria

Inclusion

  • Age \>= 18 years
  • Current treatment for RA on an outpatient basis
  • Active disease
  • Currently receiving 50 mg etanercept subcutaneously (SC) every week or 40 mg adalimumab SC every other week.
  • Considered by Investigator to be a primary non-responder to their first anti-TNFα treatment for efficacy reasons

Exclusion

  • Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA
  • History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome)
  • Previous treatment with a any biologic therapy for RA (including investigational products with the exception of etanercept or adalimumab
  • Treatment with more than one prior anti-TNFα therapy

Key Trial Info

Start Date :

March 5 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 14 2012

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT00808210

Start Date

March 5 2009

End Date

November 14 2012

Last Update

November 6 2020

Active Locations (53)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (53 locations)

1

Rheumatology Associates

Birmingham, Alabama, United States, 35205

2

NEA Baptist Clinic

Jonesboro, Arkansas, United States, 72401

3

Dr. Brigid Freyne, MD

Murrieta, California, United States, 92563

4

Agilence Arthritis and Osteoporosis Medical Center, Inc.

Whittier, California, United States, 90606

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab | DecenTrialz